The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration.
PerkinElmer may be nearing an FDA submission for a panel based on technology from the University of Washington, amid a push for state-mandated screening programs.
The company said the divestiture of its medical imaging business in the fourth quarter reduced revenues to below previous guidance.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
The agreement with PerkinElmer's Wallac Oy subsidiary will bring Mobidiag's real-time PCR-based gastrointestinal tests to a new market.
Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
Tulip Diagnostics Private provides in vitro diagnostic reagents, kits, and instruments to labs, and government and private healthcare facilities in India.
The companies will merge 10x's Chromium system and PerkinElmer's automation solutions into a combined NGS solution for researchers.
The company said the divestiture to Varian Medical Systems would allow it to concentrate on investing in high-growth parts of its business.
The company reported drops in revenues for both its human health and environmental health units, blaming challenging market conditions for the decreases.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.